Amerikanische Gesellschaft für Hirudotherapie

Cluster Headache (Episodic)

Highly investigational use for episodic cluster headache between attack cycles; very limited anecdotal data, not for active attacks.

Tier C — InvestigationalInvestigativLast updated: 2026-05-26 · Reviewed by ASH Editorial Board

Patienten-Zusammenfassung

Ist dies FDA-zugelassen fuer diese Anwendung?
Not FDA-cleared for cluster headache. FDA cleared medicinal leeches only for venous congestion in microsurgical reconstruction (K040187, 2004). Use here is investigational.
Welche Evidenz existiert?
Tier C (investigational). There are no published controlled trials. Cluster headache is one of the most painful conditions known and requires aggressive evidence-based therapy: acute attacks with high-flow oxygen via non-rebreather mask, subcutaneous sumatriptan, or intranasal zolmitriptan (the highest-evidence acute therapies); transitional prevention with corticosteroid taper or occipital nerve block; preventive therapy with verapamil (first-line), lithium, topiramate, or galcanezumab; non-invasive vagal nerve stimulation (FDA-cleared for episodic cluster); and sphenopalatine ganglion stimulation or occipital nerve stimulation for refractory cases. Onset of an acute attack is a medical emergency for symptom control.
Hauptrisiken
  • Bleeding from each bite site for 6 to 24 hours after detachment
  • Bruising over the temporal or periorbital region for 5 to 10 days
  • Local skin or, rarely, Aeromonas hydrophila infection
  • Allergic reaction to leech saliva (uncommon)
  • TRIGGER RISK: any stimulus can trigger a cluster attack during a cluster period
  • Delay of high-flow oxygen, sumatriptan, verapamil, and other proven therapies (a delay in cluster is intolerable pain)
  • Misdiagnosis - clusters are sometimes confused with secondary causes (pituitary tumor, carotid dissection) that need urgent workup
  • Placement near temporal artery in age over 50 risks giant cell arteritis being missed
Wer dies nicht in Betracht ziehen sollte
  • Patients in an active cluster period who have not optimized acute (oxygen, triptans) and preventive (verapamil) therapy
  • Patients with red-flag features (focal neurological signs, autonomic features outside attacks, age over 50 new-onset)
  • Patients with suspected secondary causes (pituitary tumor, AVM, carotid dissection)
  • Patients on anticoagulants, with hemophilia, or with severe anemia
  • Patients with active dermatitis or broken skin at planned placement sites
  • Patients on monoamine oxidase inhibitors or with cardiovascular contraindications to triptans (different issue, but triptan optimization first)
Was Sie Ihren Kliniker fragen sollten
  • Am I receiving high-flow oxygen (12 to 15 L/min via non-rebreather) for acute attacks?
  • Have I tried subcutaneous sumatriptan or intranasal zolmitriptan?
  • Am I on verapamil titrated to adequate dose for prevention?
  • Have I had MRI brain to rule out secondary causes (pituitary tumor, AVM, carotid dissection)?
  • Am I a candidate for occipital nerve block, sphenopalatine ganglion stimulation, or non-invasive vagal nerve stimulation?
  • Why is leech therapy being considered given the highly effective evidence-based options for cluster?
  • What is the practitioner's plan if I have a cluster attack during or after a session?
Wann dringende medizinische Versorgung suchen
  • Thunderclap (worst-of-life) headache, sudden severe headache (possible subarachnoid hemorrhage - 911)
  • Headache with fever, stiff neck, photophobia, or altered mental status (possible meningitis)
  • Headache with focal neurological deficit, vision change, speech difficulty, or seizure
  • Sudden severe pain with neck stiffness and Horner syndrome features (possible carotid dissection)
  • Cluster attacks that do not respond to oxygen or triptans
  • Bleeding from a bite site lasting more than 24 hours
  • Hives, facial or throat swelling, or breathing difficulty

Was dies NICHT bedeutet

  • This is not FDA-cleared for cluster headache.
  • No controlled trials support efficacy; cluster headache responds dramatically to high-flow oxygen, sumatriptan, and verapamil.
  • It does not abort an acute cluster attack; high-flow oxygen and triptans do.
  • It does not prevent cluster attacks; verapamil, lithium, topiramate, and galcanezumab do.
  • Misdiagnosis of secondary causes (pituitary, AVM, carotid dissection) can be catastrophic if delayed.

Clinical Profile

Category
neurological
ICD-10
G44.001, G44.009, G44.019
Safety tier
medium

Evidence Summary

Cluster headache is conventionally managed with high-flow oxygen and subcutaneous sumatriptan for acute attacks, and verapamil, lithium, or galcanezumab for prevention. Occipital nerve blocks and non-invasive vagus nerve stimulation are second-line preventives. No controlled clinical trial or published case series of leech therapy for cluster headache has been reported; any use is investigational and mechanistic only and is not supported by controlled data. Hirudotherapy must never be applied during an active attack; conventional acute therapy (oxygen, triptan) is non-negotiable.

Treatment specifics

How many leeches, where they are placed, how long a session lasts, and whether to repeat are clinical decisions made by a qualified provider under institutional protocol — not something to self-administer. Discuss the specifics with a clinician experienced in medicinal leech therapy. (Clinicians: switch the audience selector in the top bar to “Clinician” to view protocol detail.)

Key Trials

  1. Sharma R et al. (2018)0

Contraindications

  • Active anticoagulant therapy (warfarin INR >2.0, DOACs, heparin)
  • Hemophilia or other bleeding disorder
  • Severe anemia (Hb <10 g/dL)
  • Active bacteremia or sepsis
  • Known hypersensitivity to leech salivary proteins
  • Pregnancy (relative — first/third trimester)
  • Immunocompromised state with severe neutropenia
  • Active cluster attack (oxygen and triptan are emergent therapy)
  • Secondary cluster from undiagnosed structural lesion
  • Trigeminal autonomic cephalgia of unclear subtype

Related Conditions

Diese Website stellt Bildungsinformationen bereit und ist weder eine medizinische Beratung noch eine Diagnose oder Behandlungsempfehlung. Die medizinische Blutegeltherapie ist mit klinisch relevanten Risiken verbunden und sollte ausschließlich von qualifizierten Klinikerinnen und Klinikern unter institutionell genehmigten Protokollen durchgeführt werden. Die FDA-510(k)-Zulassung für medizinische Blutegel ist auf bestimmte Indikationen beschränkt; experimentelle und Off-Label-Diskussionen werden entsprechend gekennzeichnet. Für patientenspezifische Beratung wenden Sie sich an eine qualifizierte Gesundheitsfachkraft.

Cluster Headache (Episodic) — Hirudotherapy Evidence | ASH